Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

Eli Lilly is set to launch its popular weight-loss drug in emerging markets, including India, Brazil, and Mexico, by mid-2025 ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo ...